Diagnosis of inflammatory bowel disease according to human IgG4 and possibilities of evaluating efficacy of the therapy

  • Y. M. Stepanov Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
  • T. S. Tarasova Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
  • M. V. Stoikevych Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
  • Y. A. Gaydar Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
  • D. F. Mylostуva Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
  • О. M. Tatarchuk Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
  • O. P. Petishko Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine
Keywords: ulcerative colitis; Crohn’s disease; biomarkers; humoral immunity; plasmatic cells.


Taking into account the progress of understanding diagnosis, course prognosis, evaluation of effectiveness of therapy of inflammatory bowel disease and also differentiation diagnosis between its main forms – ulcerative colitis and Crohn’s disease, the search for efficient non-invasive markers for solving those issues is extremely relevant. The patients were divided into groups depending on nosology and severity of the course of the disease. All the patients had undergone endoscopic study for diagnosis verification and biopsy samples were taken for further detection of tissue IgG4 using the immunohistochemical method. Also, we determined concentration of serum IgG4. Increase in IgG4content in blood serum was determined in 54.0% of the cases of inflammatory bowel disease. Concentration of IgG4 in patients suffering ulcerative colitis was higher (by 2.31 and 2.46 times) compared with its level in the control group and patients with Crohn’s disease, respectively. We found relationships between the concentration of serum IgG4 and the activity of the disease. In patients with ulcerative colitis, increased tissue IgG4 was found more often than in patients with Crohn’s disease (by 2.77 times, Р < 0.05). We determined the relationship between tissue IgG4 and histological activity. Simultaneous increase in serum IgG4 and presence of tissue IgG4 during ulcerative colitis were more frequent than during Crohn’s disease (by 2.66 times). In all examined groups of patients, we determined decrease in serum IgG4 content (by 1.66 times) after treatment. Concentration of serum IgG4 and positive tissue IgG4 in ulcerative colitis patients exceeded such in Crohn’s disease patients, which may be used for differentiation diagnosis between those disease types. We determined dependence of IgG4 concentration on severity and duration of the disease, which could be used as a prognostic marker. Decrease in IgG4 content in blood serum against the background of the therapy shows that this indicator could be used as a marker of treatment efficacy. Perspectives of further studies are as follows: parameters of concentration of serum IgG4 and presence of tissue IgG4 could be used as diagnostic and prognostic biomarkers and be introduced to practice for differentiation diagnosis between ulcerative colitis and Crohn’s disease, and could be used as prognostic marker of severity of the disease and therapy efficacy.


Chen, X., Sun, W., Lin, R., Huang, Z., & Chen, W. (2018). IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4. International Journal of Clinical and Experimental Pathology, 11(9), 4537–4544.

Chen, Y., Zhang, G., Yang, Y., Zhang, S., Jiang, H., Tian, K., Arenbaoligao, & Chen, D. (2023). The treatment of inflammatory bowel disease with monoclenal antibodies in Asia. Biomedicine and Pharmacotherapy, 157, 114081.

Crescioli, S., Correa, I., Karagiannis, P., Davies, A. M., Sutton, B. J., Nestle, F. O., & Karagiannis, S. N. (2016). IgG4 characteristics and functions in cancer immunity. Current Allergy and Asthma Reports, 16(1), 7.

Cui, G., Fan, Q., Li, Z., Goll, R., & Florholmen, J. (2021). Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine, 66, 103329.

D'Alessio, S., Ungaro, F., Noviello, D., Lovisa, S., Peyrin-Biroulet, L., & Danese, S. (2022). Revisiting fibrosis in inflammatory bowel disease: The gut thickens. Nature Reviews, Gastroenterology and Hepatology, 19(3), 169–184.

Dmochowska, N., Wardill, H. R., & Hughes, P. A. (2018). Advances in imaging specific mediators of inflammatory Bowel disease. International Journal of Molecular Sciences, 19(9), 2471.

Fabián, O., & Kamaradová, K. (2022). Morphology of inflammatory bowel diseases (IBD) [Morfologie Zánětlivých Střevních Onemocnění (IBD)]. Ceskoslovenska Patologie, 58(1), 27–37.

Fleming, A., Castro-Dopico, T., & Clatworthy, M. R. (2022). B cell class switching in intestinal immunity in health and disease. Scandinavian Journal of Immunology, 95(2), e13139.

Harkness, T., Fu, X., Zhang, Y., Choi, H. K., Stone, J. H., Blumenthal, K. G., & Wallace, Z. S. (2020). Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. Annals of Allergy, Asthma and Immunology, 125(2), 190–195.

Ishikawa, H., Uruga, H., Fujii, T., Kurosaki, A., Morokawa, N., & Takaya, H. (2020). IgG4-related disease in the differential diagnosis of lung nodules. Respirology Case Reports, 8(4), e00550.

Kotani, H., Ohtsuka, T., Okada, S., Kusama, M., & Taniguchi, T. (2020). A case of IgG4-related disease presented with Kimura disease-like skin eruption, rheumatoid arthritis-like abnormality and interstitial pneumonia. Clinical and Experimental Dermatology, 45(6), 733–734.

Koutroumpakis, F., Phillips, A. E., Yadav, D., Machicado, J. D., Ahsan, M., Ramos Rivers, C., Tan, X., Schwartz, M., Proksell, S., Johnston, E., Dueker, J., Hashash, J. G., Barrie, A., Harrison, J., Dunn, M. A., Konnikova, L., Hartman, D. J., Din, H., Babichenko, D., Tang, G., & Binion, D. G. (2021). Serum IgG4 subclass deficiency defines a distinct, commonly encountered, severe inflammatory Bowel disease subtype. Inflammatory Bowel Diseases, 27(6), 855–863.

Martínez-Botas, J., Fernández-Lozano, C., Vaquero-Rey, A., & de la Hoz, B. (2023). IgE and IgG4 epitope mapping of food allergens with a peptide microarray immunoassay. Methods in Molecular Biology, 2578, 219–236.

Martín-Nares, E., Hernández-Molina, G., Baenas, D. F., & Paira, S. (2022). IgG4-related disease: Mimickers and diagnostic pitfalls. Journal of Clinical Rheumatology Practical Reports on Rheumatic and Musculoskeletal Diseases, 28(2), e596–e604.

Maslinska, M., Dmowska-Chalaba, J., & Jakubaszek, M. (2022). The role of IgG4 in autoimmunity and rheumatic diseases. Frontiers in Immunology, 12, 787422.

Nyuyki, K. D., & Pittman, Q. J. (2015). Toward a better understanding of the central consequences of intestinal inflammation. Annals of the New York Academy of Sciences, 1351, 149–154.

Peerani, F., Du, L., Lytvyak, E., Bain, V. G., Mason, A. L., Bailey, R. J., & Montano-Loza, A. J. (2022). Serum IgG4 cut-off of 70 mg/dL is associated with a shorter time to cirrhosis decompensation and liver transplantation in primary sclerosing cholangitis patients. Canadian Liver Journal, 5(1), 31–42.

Satou, A., Notohara, K., Zen, Y., Nakamura, S., Yoshino, T., Okazaki, K., & Sato, Y. (2020). Clinicopathological differential diagnosis of IgG4-related disease: A historical overview and a proposal of the criteria for excluding mimickers of IgG4-related disease. Pathology International, 70(7), 391–402.

Şimşek, H. D., Basyigit, S., Aktas, B., Vargol, E., Şimşek, G. G., Küçükazman, M., & Nazlıgül, Y. (2016). Comparing the type and severity of inflammatory bowel disease in relation to IgG4 immunohistochemical staining. Acta Gastro-Enterologica Belgica, 79(2), 216–221.

Stepanov, Y. M., Tarasova, T. S., & Stoykevich, M. V. (2021). IgG4, yak diahnostychnyi kryterii pry zapalnykh zakhvoriuvanniakh kyshechnyka (literaturnyi ohliad) [IgG4 as a diagnostic marker of inflammatory bowel disease (literature review)]. Hastroenterolohiia, 55, 74–81 (in Ukrainian).

Tanaka, A., Tazuma, S., Okazaki, K., Tsubouchi, H., Inui, K., & Takikawa, H. (2014). Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. Journal of Hepato-Biliary-Pancreatic Sciences, 21(1), 43–50.

Tang, J., Cai, S., Ye, C., & Dong, L. (2020). Biomarkers in IgG4-related disease: A systematic review. Seminars in Arthritis and Rheumatism, 50(2), 354–359.

Topal, F., Sarıtaş Yüksel, E., Ekinci, N., Pekdiker, M., Cakalağaoğlu, F., Alper, E., & Unsal, B. (2014). The prevalence of IgG4-positive plasma cell infiltrates in inflammatory bowel disease patients without autoimmune pancreatitis. The Turkish Journal of Gastroenterology, 25(5), 558–562.

Trampert, D. C., Hubers, L. M., van de Graaf, S. F. J., & Beuers, U. (2018). On the role of IgG4 in inflammatory conditions: Lessons for IgG4-related disease. Biochimica et Biophysica Acta, Molecular Basis of Disease, 1864(4 Pt B), 1401–1409.

Uo, M., Hisamatsu, T., Miyoshi, J., Kaito, D., Yoneno, K., Kitazume, M. T., Mori, M., Sugita, A., Koganei, K., Matsuoka, K., Kanai, T., & Hibi, T. (2013). Mucosal CXCR4+ IgG plasma cell contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut, 62(12), 1734–1744.

Wang, Z., Adachi, S., Kong, L., Watanabe, D., Nakanishi, Y., Ohteki, T., Hoshi, N., & Kodama, Y. (2019). Role of eosinophils in a murine model of inflammatory bowel disease. Biochemical and Biophysical Research Communications, 511(1), 99–104.

Wang, Z., Zhu, M., Luo, C., Zhen, Y., Mu, J., Zhang, W., Ouyang, Q., & Zhang, H. (2018). High level of IgG4 as a biomarker for a new subset of inflammatory bowel disease. Scientific Reports, 8(1), 10018.

Watanabe, T., Yamashita, K., & Kudo, M. (2017). IgG4-related disease and innate immunity. Current Topics in Microbiology and Immunology, 401, 115–128.

How to Cite
Stepanov, Y. M., Tarasova, T. S., Stoikevych, M. V., Gaydar, Y. A., MylostуvaD. F., TatarchukО. M., & Petishko, O. P. (2022). Diagnosis of inflammatory bowel disease according to human IgG4 and possibilities of evaluating efficacy of the therapy . Regulatory Mechanisms in Biosystems, 13(4), 412-418. https://doi.org/10.15421/022254